Home » Topics » Regulatory » EMA

EMA
RSS

CHMP issues positive opinion on Avastin biosimilar ABP-215

Nov. 13, 2017

EMA committee recommends expanding approval of Orkambi

Nov. 13, 2017

EMA's CHMP supports expanding Nplate indication

Nov. 13, 2017

FDA gives orphan status to Achillion's ACH-4471 for PNH

Nov. 8, 2017

Pegfilgrastim biosimilar from Sandoz accepted for EMA review

Oct. 31, 2017

VBL Therapeutics' VB-111 granted orphan medicinal product status in E.U.

Oct. 23, 2017

EMA grants orphan drug designation to G-100 for the treatment of follicular non-Hodgkin's lymphoma

Oct. 20, 2017

EMA grants orphan drug designation to Conatus' IDN-7314 for primary sclerosing cholangitis

Oct. 19, 2017

Ignyta's entrectinib obtains PRIME designation from EMA

Oct. 18, 2017

EMA's CHMP supports expansion of marketing authorization for Zytiga

Oct. 16, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
Other news to note for May 1, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: AC Immune, Aptose, Astrazeneca, Bioreference Health, Cardioline,...